250 related articles for article (PubMed ID: 24560635)
1. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
[TBL] [Abstract][Full Text] [Related]
2. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
3. A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation.
Mallia MB; Shinto AS; Kameswaran M; Kamaleshwaran KK; Kalarikal R; Aswathy KK; Banerjee S
Cancer Biother Radiopharm; 2016 May; 31(4):139-44. PubMed ID: 27183437
[TBL] [Abstract][Full Text] [Related]
4. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
[TBL] [Abstract][Full Text] [Related]
6. Application of rhenium-188 HEDP in bone metastases therapy.
Scheffler J; Derejko M; Bandurski T; Romanowicz G
Nucl Med Rev Cent East Eur; 2003; 6(1):55-7. PubMed ID: 14600935
[TBL] [Abstract][Full Text] [Related]
7. Rhenium-188 HEDP to treat painful bone metastases.
Li S; Liu J; Zhang H; Tian M; Wang J; Zheng X
Clin Nucl Med; 2001 Nov; 26(11):919-22. PubMed ID: 11595844
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
Liepe K; Kropp J; Runge R; Kotzerke J
Br J Cancer; 2003 Aug; 89(4):625-9. PubMed ID: 12915868
[TBL] [Abstract][Full Text] [Related]
9. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
Lange R; de Klerk JMH; Bloemendal HJ; Ramakers RM; Beekman FJ; van der Westerlaken MML; Hendrikse NH; Ter Heine R
Nucl Med Biol; 2015 May; 42(5):465-469. PubMed ID: 25662844
[TBL] [Abstract][Full Text] [Related]
10. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
11. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
Holle LH; Humke U; Trampert L; Ziegler M; Kirsch CM; Oberhausen E
Urologe A; 1997 Nov; 36(6):540-7. PubMed ID: 9487590
[TBL] [Abstract][Full Text] [Related]
12. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
Róka R; Séra T; Pajor L; Thurzó L; Láng J; Csernay L; Pávics L
Orv Hetil; 2000 May; 141(19):1019-23. PubMed ID: 10846424
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
14. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
Palmedo H; Bender H; Schomburg A; Grünwald F; Schöneich G; Zamorra P; Reichmann K; Dierke-Dzierzon C; Mallmann P; Biersack HJ
Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
[TBL] [Abstract][Full Text] [Related]
15. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
[TBL] [Abstract][Full Text] [Related]
16. Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDP.
Lange R; Ter Heine R; van der Gronde T; Selles S; de Klerk J; Bloemendal H; Hendrikse H
Eur J Pharm Sci; 2016 Jul; 90():96-101. PubMed ID: 26772897
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
Liepe K; Franke WG; Kropp J; Koch R; Runge R; Hliscs R
Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
[TBL] [Abstract][Full Text] [Related]
18. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
19. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
20. Significant reduction of the mass of bone metastasis 1 year after rhenium-186 HEDP pain palliation therapy.
Liepe K; Kropp J; Hliscs R; Franke WG
Clin Nucl Med; 2000 Nov; 25(11):901-4. PubMed ID: 11079588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]